13:00-14:30
Solvay Pharmaceuticals Sponsored Symposium

The Impact of Continuous Dopaminergic Stimulation on Motor and non-Motor Symptoms of Parkinson’s Disease
Chair: W. Poewe, Austria

The rationale for continuous dopaminergic stimulation in the treatment of Pakinson´s disease
M.Mouradian, USA

Continuous dopaminergic stimulation in Spanish patients with late PD
F. Valldeoriola , Spain

Duodopa - relevance for non-motor symptoms in Parkinson´s disease
P. Odin, Germany

15:00-16:30
UCB Sponsored Symposium

Early Non-Motor Symptoms Associated with Idiopathic Parkinsons Disease
Chair: H. Reichmann, Germany

Sleep Disturbances
E. Tolosa, Spain

Olfactory Disturbances
H. Reichmann, Germany

Gastrointestinal Disturbances
D. Woitalla, Germany

Podium Discussions: Should there be consequences for diagnosis and therapy?

17:00-18:30
Opening Session and Plenary

Welcome addresses
H.Reichmann, Germany
A.D.Korczyn, Israel

WFN Research Group
E. Wolters, The Netherlands

Key-note Lectures
Lewy bodies in the brain-What do they teach us?
W. Olanow, USA

Are falls in PD due to cognitive failure?
N. Giladi, Israel

Role of the basal ganglia in non-motor manifestation of PD
J. Obeso, Spain

08:00-09:30
Plenary Session

Chairs:
A.D. Korczyn, Israel
E. Wolters, The Netherlands

History of mental dysfunction in PD
C. Goetz, USA

Apathy and Depression
W. Poewe, Austria

Diagnosis of Parkinson’s disease
dementia
B. Dubois, France

09:40-11:10
Scientific Session

Neuropathology
Chairs:
K. Jellinger, Austria
R. von Kummer, Germany

Correlation between Braak stages and PD
E. Wolters, The Netherlands

Pathology of the autonomic nervous system in PD
K. Jellinger, Austria

Brainstem pathology and nonmotor symptoms in PD
L. Grinberg, Brazil

09:40-11:10
Scientific Session

Emotional Communication in PD
Chairs:
R. Dengler, Germany
E. Pourcher, Canada

Changes of emotional speech in PD
C. Schroeder; R.Dengler
Germany

Social implications of
communicating with Parkinson’s disease
M. Pell, Canada

The role of the basal ganglia in
emotional prosodic processing
S. Kotz, Germany

Perception of effect in PD or Dimensional approach in depression in PD
E. Pourcher, Canada

09:40-11:10
Scientific Session

Sleep
Chairs:
TBA

Relationship between RLS and PD
W. Oertel, Germany

REM sleep behavior disorder
B. Boeve, USA

Insomnia and somnolence in PD
R. Chaudhuri, UK

Sleep problems in non-PD movement disorders
E. Tolosa, Spain

11:30-13:00
GE HEALTH CARE Sponsored Symposium

Dopamine transporter SPECT in the differential diagnosis of dementia – a new clinical tool

Predictive diagnostic accuracy of 123I -FP-CIT SPECT in possible
dementia with Lewy bodies: a 12 month follow-up study

Dementia with Lewy bodies: A Comparison of clinical diagnosis, FP-CIT SPECT imaging and AUTOPSY in 22 cases

Practical application of DaTSCAN

14:00-15:30
Scientific Session

Diagnostic markers
Chairs:
P. Riederer, Germany
TBA

PET Imaging techniques
D. Brooks, UK

MEG
C. Stam, The Netherlands

Comparison of biochemical markers in PD-dementia and Alzheimer´s disease
M. Gerlach, Germany

TBA

Mental dysfunctions in other Movement Disorders
Chairs:
M.Emre, Turkey
TBA

Cognitive and behavioural aspects of CBGD and PSP
A. Kertesz, Canada

Neuropsychiatic changes in MSA
G. Wenning, Austria

Dementia in essential tremor
E. Louis, USA

Cognitive changes in spinocerebellar degeneration
T. Klockgether, Germany

16:00-17:30
Merck Serono Sponsored
Symposium
The new face of PD: the tip of the
iceberg?
Chairs:
P. Barone, Italy
TBA

Prevalence of cognitive deficits in PD
P. Calabrese, Germany

Can we talk of early cognitive impairement in PD?
J. Kulisevsky, Spain

Neuropathology of non-motor
symptoms in PD,TBA
Burden of non-motor symptoms
in PD:epidemiology, TBA

17:30-19:00
Scientific Session

Questionnaires and Rating Scales
Chairs:
R. Dodel, Germany
F. Stocchi, Italy

Non-motor scales and questionnaires
C. Goetz, USA

Impulse Control Disorders
M. Stacey, USA

Dementia
P. Calabrese, Germany

Composite rating scales
P. Martinez-Martin, Spain

17:30-19:00
Scientific Session

Pharmacoeconomics and regulatory aspects
Chairs:
Th. Klockgether, Germany

Pharmacoeconomics in PD and PDD
R. Dodel, Germany

Regulatory prerequisites for studies in PD
K.Broich, Germany

EBM & Pharmacoeconomics
C. Sampaio, Portugal

17:30-19:00
Scientific Session

Olfaction and Parkinsonism: What we know and how you can use it in your clinic
Chairs:
J. Duda, USA
T. Hummel, Germany

Olfaction in PD and aging: same or different process
CH. Hawkes, UK

Olfactory system pathology as a model of Lewy neurodegenerative disease
J.Duda, USA

How to asses olfaction in the clinic and in the lab
T. Hummel, Germany

Can smell tests predict PD?
H.W. Berendse, The Netherlands

San Francisco/Oakland Bay Bridge Weldere Study:olfactory function
R. Doty, USA

08:30-09:30
Plenary Session

Hereditary types of
neurodegenerative disorders
Chairs:
H.Reichmann, Germany

Genetics of dementia and psychosis
in PD
O. Riess, Germany

Are sporadic and genetic PD equally susceptible to dementia?
R. Inzelberg, Israel

Parkinsonism/depression/hypoventil ation syndrome (Perry Syndrome)
Z. Wszolek, USA

09:30-11:00
Scientific Session

Clinical Manifestations
Chairs:
B. Dubois, France
M. Stacey, USA

Suicide in PD- is it really so rare?
V. Kostic, Serbia

Frontal-striatal abnormalities underlying behaviours within the compulsive-impulsive spectrum
O.van den Heuvel, The Netherlands

The natural history of mental impairment in PD
I. Litvan, USA

Apraxia in movement disorders
M. Hallett, USA

09:30-11:00
Scientific Session

Dopamine dysregulation
disorders
Chairs:
TBA

Hypersexuality in PD
F. Stocchi, Italy

Gambling in PD
V. Voon, USA

Punding
S. Factor, USA

Addiction to dopaminergic drugs
E. Melamed, Israel

09:30-11:00
Scientific Session

Speech in Parkinson's Disease
Chairs:
I.Rektorova, Czech Republic

Functional imaging of speech in PD– an fMRI study
I.Rektorova, Czech Republic

Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech
S. Pinto, UK

11:30-13:00
Lundbeck/Teva Sponsored Symposium
Rasagiline - providing patients with key benefits in the treatment of Parkinson’s disease

Opening
H.Reichmann, Germany

Rasagiline in the treatment of early PD
F. Stocchi, Italy

Treatment of non motor symptoms in the course of Parkinson's disease
H.Reichmann, Germany

Specific benefits of rasagiline in the treatment of moderate to advanced Parkinson's disease
N. Giladi, Israel

14:00-15:30
Scientific Session

New aspects in PD Therapy
Chairs:
A. Ludolph, Germany
A.Schapira, UK

DBS in non-motor disorders
A. Lozano, Canada

Effects of TMS on non-motor functions in PD
Y. D. Van Der Werf, The
Netherlands

Stem Cell Therapy in PD
A. Storch, Germany

PD Treatment 2020
M. Youdim, Israel

14:00-15:30
Scientific Session

Sensory problems in PD
Chairs:
TBA
D. Truong, USA

Visual impairment
I.Bodis-Wollner, USA

Control of the vertical postural in
PD: vestibular or proprioceptve function?
J.P Azulay, France

Pain
O. Rascol, France

The nature of visual deficits in dementia with lewy bodies and posterior cortical atrophy
C. Metzler-Baddeley, UK

Drug Therapy
Chairs:
TBA

Is it the drug or the disease?
Non motor manifestations in PD
O. Rascol, France

Placebo responses in PD
J. Stoessel, Canada

Therapy adherence in PD: Results of a multi-centre European study
D. Grosset, UK

Alternative therapies in PD
H. Przuntek, Germany

16:00-17:30
Scientific Session

Epidemiology
Chairs:
I. Litvan, USA
O. Rascol, France

Epidemiology of Dementia in PD
D. Aarsland, Norway

Epidemiology of Depression in PD
H.U. Wittchen, Germany

Epidemiological aspects of psychosis
G. Fenelon, France

16:00-17:30
Scientific Session

Transcranial sonography
Chairs:
R. Benecke, Germany
A. Guekht, Russia

Technical aspects and reality of transcranial sonography in PD
D. Skoloudik, Czech Republic

Transcranial sonography findings
related to depression in PD
D. Berg, Germany

Transcranial sonography findings
related to dementia and other non-motor features of PD
U. Walter, Germany

16:00-17:30
Free Communications

Non-motor fluctuations
K. Bayulkem, Turkey

17:30-19:00
Boehringer Ingelheim Sponsored Symposium

Perspectives in Parkinson's Disease
Chairs:
O. Rascol, France
H.Reichmann, Germany

Introduction
Optimal Motor Symptoms Control- Is That All Parkinson's Disease?
A. Storch, Germany

Pharmacologic Advances in
Dopaminergic Treatment
O. Rascol, France

Management of Depression in
Parkinson's Disease
A. Leentjens, The Netherlands

Prospects in Neuroprotection – Is the future now?
A. Schapira, UK

Panel Discussion
Conclusion

08:30-09:30
Plenary Session
Chairs:
S. Chouinard, Canada
TBA

Autonomic dysfunction and cognitive impairment in PD?
C. Mathias, UK

Is the cholinergic system involved in cognitive impairment in PD?
E. Hirsch, France

Compensatory mechanisms related to non-motor manifestations of PD
A. Schapira, UK

09:30-11:00
Scientific Session

Drug Treatment
Chairs:
D. Aarsland, Norway
E. Ott, Austria

Does dopaminergic medication affect the prevalence and phenomenology of depression in PD?
A. Leentjens, The Netherlands

Treatment of anhedonia in PD
M. Yamamoto, Japan

Treatment of psychosis in PD
M.J. Rabey, Israel

09:30-11:00
Special Session

German study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)
Chairs:
P. Riederer, Germany
H.-U. Wittchen, Germany

Dementia and Cognitive Impairment in Parkinson's Disease- Results from the GEPAD study
R. Dodel, Germany

Sensitivity and Specifity of the Parkinson Neuropsychometric Dementia Assessment (PANDA)
E. Kalbe, Germany

Depression in Parkinson's Disease with and without dementia: Common and specific factors
I. Heuser, Germany

Correlates and sequealae of PD
with dementia and depression
O. Riedel, Germany

Iron toxicity
A. Friedman, Poland

11:30-13:00
Scientific Session

Autonomic Manifestation in Parkinsonian Syndromes
Chairs:
R. Chaudhuri, UK
TBA

Challenges in the treatment of sexual dysfunction in PD
G. Bronner, Israel

Gastrointestinal dysfunction in PD
W. Jost, Germany

Cardiovascular dysfunction in PD
T. Ziemssen, Germany

Orthostatic hypotension and nonmotor symptoms in PD
D. Burn, UK

11:30-13:00
Scientific Session

Deep brain stimulation
Chairs:
G. Deuschl, Germany
E. Ruzicka, Czech Republic

Neuropsychological and psychiatric side effects of DBS: Results from a randomized trial against best medical
G. Deuschl , Germany

Is the STN involved in cognition?
I. Rektor, Czech Republic

Psychiatric indications and contraindications to DBS in PD& other movement disorders
A. Kupsch, Germany

Depression in DBS and DBS in depression
A. Troster, USA

11:30-13:00
Scientific Session

Movement disorders and
psychiatric diseases
Chair
Psychiatric aspects of movement
disorders
P. Odin, Germany

Non organical movement disorders
M. Hallett, USA

Movement disorders in psychiatric diseases
S. Factor, USA

Imaging of hysterical movement disorders
K.L. Leenders